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Abstract
Hypophosphatasia is a rare inherited disorder characterized by defective bone and teeth
mineralization, and deficiency of serum and bone alkaline phosphatase activity. The prevalence of
severe forms of the disease has been estimated at 1/100 000.
The symptoms are highly variable in their clinical expression, which ranges from stillbirth without
mineralized bone to early loss of teeth without bone symptoms. Depending on the age at diagnosis,
six clinical forms are currently recognized: perinatal (lethal), perinatal benign, infantile, childhood,
adult and odontohypophosphatasia. In the lethal perinatal form, the patients show markedly
impaired mineralization in utero. In the prenatal benign form these symptoms are spontaneously
improved. Clinical symptoms of the infantile form are respiratory complications, premature
craniosynostosis, widespread demineralization and rachitic changes in the metaphyses. The
childhood form is characterized by skeletal deformities, short stature, and waddling gait, and the
adult form by stress fractures, thigh pain, chondrocalcinosis and marked osteoarthropathy.
Odontohypophosphatasia is characterized by premature exfoliation of fully rooted primary teeth
and/or severe dental caries, often not associated with abnormalities of the skeletal system.
The disease is due to mutations in the liver/bone/kidney alkaline phosphatase gene (ALPL; OMIM#
171760) encoding the tissue-nonspecific alkaline phosphatase (TNAP). The diagnosis is based on
laboratory assays and DNA sequencing of the ALPL gene. Serum alkaline phosphatase (AP) activity
is markedly reduced in hypophosphatasia, while urinary phosphoethanolamine (PEA) is increased.
By using sequencing, approximately 95% of mutations are detected in severe (perinatal and
infantile) hypophosphatasia.
Genetic counseling of the disease is complicated by the variable inheritance pattern (autosomal
dominant or autosomal recessive), the existence of the uncommon prenatal benign form, and by
incomplete penetrance of the trait. Prenatal assessment of severe hypophosphatasia by mutation
analysis of chorionic villus DNA is possible. There is no curative treatment for hypophosphatasia,
but symptomatic treatments such as non-steroidal anti-inflammatory drugs or teriparatide have
been shown to be of benefit. Enzyme replacement therapy will be certainly the most promising
challenge of the next few years.
Disease name and synonyms
• Hypophosphatasia
• Phosphoethanolaminuria
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• Rathbun disease
• HOPS
Definition and diagnostic criteria
Hypophosphatasia (OMIM 146300, 241500, 241510) is
an inherited disorder characterized by defective bone and
teeth mineralization and deficiency of serum and bone
alkaline phosphatase (AP) activity.
Epidemiology
The birth prevalence of severe hypophosphatasia was esti-
mated to be 1/100 000 on the basis of pediatric hospital
records in USA [1]. The incidence of moderate forms was
never estimated but it is expected to be much higher, due
to the number of patients with dominant forms carrying
the same mutations than those found in recessive hypo-
phosphatasia.
Clinical description
Clinical expression ranges from stillbirth without miner-
alized bone to pathologic fractures developing only late in
adulthood [2]. Depending on the age at diagnosis, six
clinical forms are currently recognized: perinatal (lethal),
infantile, childhood, adult, odontohypophosphatasia
and a rare benign prenatal form characterized by in utero
detection but much better prognosis than other prenatal
forms (Table 1). However, it should be noticed that these
clinical subtypes overlap, for instance infantile and child-
hood hypophosphatasia share some clinical symptoms,
and patients with adult hypophosphatasia often had
some clinical symptoms already in childhood.
In the lethal perinatal form, the patients show markedly in
utero  impaired mineralization. They have skin-covered
osteochondral spurs protruding from the forearms or legs
[3]. These spurs are often diagnostic for hypophosphata-
sia. Some infants survive a few days but have respiratory
complications due to hypoplastic lungs and rachitic
deformities of the chest. Other symptoms include apnea,
seizures and marked shortening of the long bones. In the
rare prenatal benign form, despite prenatal symptoms,
there is a spontaneous improvement of skeletal defects.
In the prenatal benign form, despite prenatal symptoms,
there is a spontaneous improvement of skeletal defects
[4,5]. The patients manifest limb shortening and bowing
and often dimples overlaying the long bones deformities,
and some ultrasounds revealed progressive improvement
of the skeletal deformities and mineralization during the
third trimester of the pregnancy [4,6].
Patients with the infantile form may appear normal at
birth; however, the clinical signs of hypophosphatasia
appear during the first six months. This form also has res-
piratory complications due to rachitic deformities of the
chest. Despite the presence of an open fontanelle, prema-
ture craniosynostosis is a common finding that may result
in increased intracranial pressure. Radiographs show
widespread demineralization and rachitic changes in the
metaphyses. Hypercalcemia also is present, explaining in
part a history of irritability, poor feeding, anorexia, vom-
iting, hypotonia, polydipsia, polyuria, dehydratation, and
constipation. Increased excretion of calcium may lead to
renal damage. In infants who survive, there is often spon-
taneous improvement in mineralization and remission of
clinical problems, with the exception of craniosynostosis
[7]. Short stature in adulthood and premature loss of
deciduous teeth are also common, but the long-term out-
look can be favorable [8].
Skeletal deformities, such as dolichocephalic skull and
enlarged joints, a delay in walking, short stature, and wad-
dling gait accompany the childhood form. Signs of intrac-
ranial hypertension or failure to thrive are typical [2,9,10].
A history of fractures and bone pain usually exists as well.
Focal bony defects near the ends of major long bones may
be observed and help point to the diagnosis. Secondary
metabolic inflammation seems to be common in the
bone of patients [11] and hyperprostaglandinism affects
the clinical severity [12]. Premature loss of dentition is
common with the incisor teeth often being the first
affected. Spontaneous remission of bone disease has been
described, but the disease may re-appear in middle or late
adulthood.
The adult form presents during middle age. The first com-
plaint may be foot pain, which is due to stress fractures of
the metatarsals. Thigh pain, due to pseudofractures of the
femur, also may be a presenting symptom. There is also a
predilection for chondrocalcinosis and marked osteoar-
thropathy later in life. Upon obtaining an in-depth his-
tory, many of these patients will reveal that they had
premature loss of their deciduous teeth [13,14].
Odontohypophosphatasia  is characterized by premature
exfoliation of fully rooted primary teeth and/or severe
dental caries, often not associated with abnormalities of
the skeletal system. The anterior deciduous teeth are more
likely to be affected and the most frequent loss involves
the incisors [15]. Dental X-rays show reduced alveolar
bone, enlarged pulp chambers and root canals. Although
the only clinical feature is dental disease, biochemical
findings are generally indistinguishable from those in
patients with mild forms of hypophosphatasia (adult and
childhood). Odontohypophosphatasia should be consid-
ered in any patient with a history of early unexplained loss
of teeth or abnormally loose teeth on dental examination
[8].Orphanet Journal of Rare Diseases 2007, 2:40 http://www.OJRD.com/content/2/1/40
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Etiology
The disease is due to mutations in the liver/bone/kidney
alkaline phosphatase gene (ALPL; OMIM# 171760)
encoding the tissue-nonspecific alkaline phosphatase
(TNAP or TNSALP). TNAP is a phosphomonoesterase of
507 residues, anchored at its carboxyl terminus to the
plasma membrane by a phosphatidylinositol-glycan moi-
ety [16]. The enzyme is physiologically active in its
dimeric form and cleaves extracellular substrates pyri-
doxal-5'-phosphate (PLP), phosphoethanolamine (PEA)
and inorganic pyrophosphates (PPi). Its exact function in
bone and dental mineralization is still unclear but
involves hydrolysis of PPi [17], and perhaps mammalian-
specific activities such as collagen [18] and calcium bind-
ing [19]. The TNAP  gene is located on chromosome
1p36.1 [20] and consists of 12 exons distributed over 50
kb [21]. The gene is subject to high allelic heterogeneity
[22] and more than 190 distinct mutations have been
described [23]. Most of them (79%) are missense muta-
tions. This variety of mutations results in highly variable
clinical expressivity and in a great number of compound
heterozygous genotypes.
Genotype-Phenotype correlations
Attempts to assess the relative importance of missense
mutations and the genotype-phenotype relationship were
performed on the basis of clinical data from patients,
transfection studies [24-35], computer-assisted modeling
[19,27], and studies of the biochemical properties of AP
in cultured fibroblasts of patients [36] or transfected cells
[37]. These experiments allowed to study cell localization,
degradation and alkaline phosphatase activity of mutant
proteins. A good correlation was observed between the
severity of the disease and in vitro enzymatic activity of the
mutant protein [27,28,30,38]. Patients with mild hypo-
phosphatasia carry at least one mutation that, when
tested, exhibits significant residual enzymatic activity,
while patients with severe hypophosphatasia carry muta-
tions that, when tested, mostly do not product enzymatic
activity. By using immunofluorescence and biochemical
treatments, various mutations were characterized for their
cell localization and their degradation [25,26,28,29,32-
34,39,40]. These studies showed that most of the mis-
sense mutations found in severe hypophosphatasia pro-
duced a mutant protein that failed to reach the cell
membrane, was accumulated in the cis-gogi and was sub-
sequently degraded in the proteasome. By contrast, the
missense mutations responsible for mild hypophosphata-
sia were found to be at least in part correctly localized to
the cell membrane. By using the crystal structure of the E.
coli alkaline phosphatase [41], and then the crystal struc-
ture of the human placental alkaline phosphatase [42],
3D models of the TNAP were built and used to localize the
hypophosphatasia mutations in the molecule [19,27].
The severe missense mutations were shown to mostly
affect residues localized in crucial domains of the protein
while mutations found in mild forms affected residues
more randomly dispatched on the molecule. Finally, and
interestingly, the complementary approach consisting in
in vitro alkaline phosphatase measurement, immunofluo-
rescence, biochemical treatments and 3D modeling con-
Table 1: The six clinical forms of hypophosphatasia.
Clinical form Inheritance Bone symptoms Dental symptoms Clinical diagnosis
Perinatal lethal AR Hypomineralization
Osteochondral spurs
na Radiographs
Ultrasonography
Prenatal benign AD Bowing of long bones
Benign post-natal
na Ultrasonography
Clinical examination
Infantile AR Craniosynostosis
Hypomineralization 
Rachitic ribs
Hypercalciuria
Premature loss of
deciduous teeth
Clinical examination
Biology (serum AP activity, PEA 
and PLP). 
Radiographs
Childhood AR (frequent) 
or AD (rare)
Short stature Skeletal
deformity Waddling gait
Bone pain/fractures
Premature loss of
deciduous teeth
Adult AR or AD Stress fractures: metatarsal, 
tibia Osteoarthritis
+/-
Odontohypophosphatasia AR or AD Loss of alveolar bone Exfoliation (incisors). 
Reduced thickness of the 
dentin.
Enlarged pulp chambers of 
teeth. 
Dental caries
Clinical examination. 
Biology (serum AP activity, PEA 
and PLP).
na: not applicable; 
AR : autosomal recessive; 
AD: autosomal dominant.Orphanet Journal of Rare Diseases 2007, 2:40 http://www.OJRD.com/content/2/1/40
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verged to give a view of the severity of a mutation (Table
2).
The dominant effect of TNAP mutations
Dominant transmission of hypophosphatasia has been
suggested on the basis of pedigree and laboratory data
[13,43-45]. More recently, mutations responsible for this
condition were identified: c.1133A>T (D361V) [46,47],
c.346G>A (A99T) [48-50], c.188G>T (G46V), c.550G>T
(R167W) and c.1433A>T (N461I) [49], c.323C>T (P91L)
and c.1240C>A (L397M) [50], c.1259G>C (G403A),
c.1402G>A (A451T) and c.1427A>C (E459A) (our
unpublished data). In vitro, these mutations were shown
to inhibit the normal monomer in the heterodimer made
of mutant and normal proteins, resulting in decreased lev-
els of alkaline phosphatase activity. Instead of the 50%
expected in heterozygotes, alkaline phosphatase activities
were found to range from 20% to 40% of wild-type [49].
The most strong in vitro inhibition was found with muta-
tions D361V and G46V, two mutations responsible for
the benign prenatal form of hypophosphatasia. Interest-
ingly, parents of patients affected with benign prenatal
hypophosphatasia express only very mild symptoms
(mostly premature loss of teeth) or even, may be com-
pletely unaffected [4,5,47]. This is also the case of families
with mild hypophosphatasia due to dominant missense
mutations. So, dominance is sometimes difficult to dem-
onstrate by using familial analysis, since expression of the
disease may be highly variable, with parents of even
severely affected children showing no or extremely mild
Table 2: 
Class Cell localization Degradation, other 
features
3D model localization Mutation and reference AP activity 
(% wild type)
1 Intracellular accumulation; 
fails to move beyond the cis-
Golgi
Degradation in the 
proteasome
Functional domains 
(homodimer interface, 
calcium binding site, active 
site)
R54C (c.211C>T), [29] 0
N153D (c.508A>G) [32] 0
I201T (c.653T>C) [40] 0
E218G (c.704A>G) [19]; 
[26]
0
D277A (c.881A>C) [29] 0
D289V (c.917A>T) [33] 0
G317D (c.1001G>A) [25] 0
2 Intracellular accumulation; 
fails to move beyond the cis-
Golgi
Degradation in the 
proteasome
Not localized in a particular 
domain
A162T (c.535G>A) [26]; 
[29]
18
G232V (c.746G>T) [40] 34
3 Cell membrane and 
cytoplasme
Not localized in a particular 
domain
F310L c.979T>C [28] 72
E174K (c.571G>A) [40] 88
I473F (c.1468A>T) [40] 37
Active site vicinity G438S (c.1363G>A) [40] 71
4 Cell membrane Not localized in a particular 
domain
A115V (c.395C>T) [34] 17
Intracellular localization; 
absence on cell surface
Large-sized secretory 
protein lacking GPI; 
aggregation due to 
disulphide bonds beween 
new cystein residues
c.1559delT [35] 28
Cell membrane Disulphide bond between 
new cystein residues
Crown domain R433C (c.1348C>T) [39] 4
Attempt to classify the ALPL gene mutations according to site-directed mutagenesis, in vitro alkaline phosphatase activity assays, and cell 
localization by immunofluorescence. Only mutations studied for all these parameters are shown. Class 1 represents the most severe mutations 
resulting in mutant proteins accumulated in the cytoplasm, subsequently degraded, and therefore producing no in vitro residual activity. These 
mutations affect residues of functional domains of the enzyme and were mostly found in patients with severe hypophosphatasia. Mutations of class 
2 are also accumulated in the cell but exhibit low but significant in vitro residual activity and could be therefore degraded with delay. These 
mutations, that do not affect particular functional domains of the protein, must be also considered as severe alleles. Mutations of class 3 are in part 
accumulated in the cytoplasm but also in part reach the cell membrane. They exhibit high in vitro residual activity and except G438S, do not affect 
residues of functional domains. These mutations are observed in patients with mild forms of hypophosphatasia. Class 4 regroups particular 
mutations not assignable to the above classes.
Nucleotides numbering is given according to [77] and the Nomenclature Working Group [78]: the first nucleotide (+1) corresponds to the A of the 
ATG initiation codon. Amino acids numbering is given according to a non-standardized nomenclature [77] taking into account of a 17-residues 
signal peptide,i.e. the ATG initiation codon is numbered as residue minus (-)17.Orphanet Journal of Rare Diseases 2007, 2:40 http://www.OJRD.com/content/2/1/40
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symptoms of the disease [2,4]. This may be attributable
both to the progressive improvement of affected patients
from infancy to adulthood [13,36,51,52] and to epige-
netic factors involved in the variable expression of the dis-
ease. It is possible that in particular stages of development
alkaline phosphatase requirements are beyond the capac-
ity of the heterozygous cell, resulting in hypophosphata-
sia symptoms. Then, AP requirements may be less
important and filled by the heterozygous cell, which may
explain the improvement in adult patients. It is also pos-
sible that the maternal alkaline phosphatase plays a role
via fetal-maternal exchanges, as suggested by the prenatal
benign form that seems to be observed only when the
mutation is inherited from the mother [4-6].
Diagnostic methods
In addition to clinical and radiographic examinations (see
clinical description), hypophosphatasia diagnosis is
based on laboratory assays, and since 1990s, molecular
biology which appears to be very effective.
Laboratory assays
Total serum AP activity is markedly reduced in hypophos-
phatasia. Thus, the diagnosis can be suggested in individ-
uals in whom serum AP activity is clearly and consistently
subnormal. In general, the more severe the disease, the
lower the serum AP activity level appropriate for age [2].
However, AP activity is only a helpful diagnostic indicator
as other conditions may also show this finding: early preg-
nancy, drug administration, hypothyroidism, anemia,
celiac disease etc. It must be also noticed that serum AP
dramatically varies with age and sex.
Increased urinary phosphoethanolamine (PEA) levels
supports a diagnosis of hypophosphatasia but is not
pathognomonic. It is also observed in a variety of other
conditions, including several metabolic bone diseases,
and some hypophosphatasia patients may have normal
PEA excretion. In fact, the demonstration that PEA is also
a natural substrate of TNAP in vivo remains to be con-
firmed [53].
Increased pyridoxal 5'-phosphate (PLP) may be a sensitive
marker for hypophosphatasia. [2].
Heterozygous carriers of the severe forms are usually clin-
ically normal but often show modestly reduced serum AP
activity and increased urinary PEA [54].
Molecular biology
Screening for mutations in the TNAP gene is essential to
confirm the hypophosphatasia diagnosis when biochem-
ical and clinical data are not clear enough, to offer genetic
counseling or to offer molecular prenatal diagnosis to
families affected by severe forms of the disease (see
below). Clinical and biochemical data may not always
distinguish hypophosphatasia from other skeletal dis-
eases such as osteogenesis imperfecta. Mutation screening
may be performed by single-stranded conformation poly-
morphism (SSCP) or denaturing gradient gel electro-
phoresis (DGGE) followed by sequencing of exons
exhibiting variants [55-62], by direct sequencing of the
cDNA [36,46,63] or by direct sequencing of genomic
sequences [30,64-67]. The exons are small and few in
number, making relatively easy the analyze. However, the
fact that the mutations are spread over all the exons often
means that the whole coding sequence has to be analyzed.
In addition, some mutations remain undetectable despite
of exhaustive sequencing of the coding sequence, intron-
exon borders and untranslated exons. This may be due to
mutations lying in intronic or regulatory sequences, but
also to the expression of heterozygous mutations, espe-
cially in moderate (childhood, adult and odonto-) hypo-
phosphatasia. By using sequencing, approximately 95%
of mutations are detected in severe (perinatal and infan-
tile) hypophosphatasia, while patients with mild forms
often carry only one detected mutated allele. This may be
due to expression of the disease at the heterozygous state
in some of these patients.
Differential diagnosis
• Osteogenesis imperfecta
• Rickets
• Achondrogenesis
Antenatal diagnosis
Prenatal assessment of severe hypophosphatasia may be
performed in couples with a previous affected child or a
previous affected pregnancy. Mutation analysis of chori-
onic villus DNAs is now well documented [68-71] and is
routinely performed in few laboratories. It seems that
mutation analysis is more reliable than AP assay of chori-
onic villus sampling at least for heterozygote detection
where low AP values may be misinterpreted [71]. Prenatal
and postnatal diagnoses were also reported by using
linked or intragenic polymorphisms [20,72]. In pregnan-
cies with clinical symptoms detected by ultrasound but no
familial history of hypophosphatasia, the prenatal diag-
nosis by mutation analysis remains possible. However,
such analyze is difficult, due to the time needed for the
ALPL  gene sequencing, and may not always lead to a
result.
Genetic counseling
Genetic counseling of hypophosphatasia is complicated
by the inheritance that may be autosomal dominant or
autosomal recessive, the existence of the uncommon pre-
natal benign form [4,5], the variable expression of the dis-Orphanet Journal of Rare Diseases 2007, 2:40 http://www.OJRD.com/content/2/1/40
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ease in heterozygotes, the probable effect of ALPL gene
polymorphisms, and the possible effect of mutations and
polymorphisms of other genes that may modulate the
hypophosphatasia phenotype (modifier genes).
Severe forms of the disease (perinatal and infantile) are
transmitted as an autosomal recessive trait, while both
autosomal recessive and autosomal dominant transmis-
sion have been shown in clinically milder forms [13,43-
45]. Therefore, the risk of recurrence of severe forms is
25%. In moderate forms, it may be 25% (recessive trans-
mission), 50% (dominant transmission) or still different
(less than 50%) due to the variable expressivity of domi-
nant forms [49,50]. The mutations detected in dominant
forms and responsible for moderate hypophosphatasia
are also found in severe recessive hypophosphatasia, asso-
ciated to other mutations [48-50]. These mutations have a
dominant negative effect due to the inhibition of AP activ-
ity of the wild-type/mutant heterodimer [47,49], or due to
intracytoplasmic sequestration of the heterodimer [Lia-
baldini et al., in preparation]. Testing patient's relatives is
useful since heterozygotes may express a mild form of the
disease. In regard to the frequency of the disease, testing
spouses of carriers is not primordial unless there is an his-
tory of consanguinity.
Management including treatment
There is no curative treatment of hypophosphatasia, but
symptomatic treatments are starting to be used in addi-
tion to orthopedic management. Treatments with zinc
and magnesium (catalytic ions of the enzyme), and pyri-
doxal 5'-phosphate were reported to not significantly
improve the patient's condition. However, the high clini-
cal heterogeneity and the fact that the disease is rare make
almost impossible controlled clinical trials. Preliminary
results suggest that dietary phosphate restriction could be
helpful in hypophosphatasia [73]. Non-steroidal anti-
inflammatory drugs were shown to significantly improve
the clinical features of childhood hypophosphatasia,
especially in regard to pain [12,74] and to the secondary
metabolic inflammation resulting from the disease [11].
Teriparatide (the recombinant human parathyroide hor-
mone PTH 1–34) was successfully used to improve and
resolve metatarsal stress fractures in adult hypophos-
phatasia [62].
In 1997, MP Whyte's group (Saint-Louis, MI, USA)
attempted to treat an 8-month-old girl affected with
highly severe hypophosphatasia by bone marrow cell
transplantation [75]. The patient was given T-cell-
depleted, haplo-identical marrow from her healthy sister,
and significant and prolonged clinical and radiographic
improvement were observed. Another 9-month-old girl
suffering from similar course of infantile hypophosphata-
sia was treated by using bone fragments and cultured oste-
oblasts [76]. Seven years after transplantation, the patient
was reported to be active and growing, and having the
clinical phenotype of the more mild childhood form of
hypophosphatasia [76]. These results suggest that donor
bone fragments and marrow may provide precursor cells
to form TNAP replete osteoblasts that can improve miner-
alization [75,76]. Another interesting way of treatment
would be to act onto the expression of the plasma cell
membrane glycoprotein-1 (PC-1) gene, an antagonist of
the TNAP gene [17]. Indeed, it has been shown in mice
that inactivation of the Pc-1 gene in TNAP-knock-out mice
allows to restore the normal bone phenotype [17].
Finally, enzyme replacement therapy by using a substitu-
tive enzyme targeting mineralized tissue should be the
most promising challenge of the next few years.
Prognosis
The perinatal form is almost always lethal within days or
weeks, and around one half of patients with the infantile
form dye from respiratory complications. Longevity stud-
ies were not reported in the infantile and childhood
forms. Patients affected with adult or odontohypophos-
phatasia are believed to have normal lifespan.
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